


CREATING GROWTH, ENHANCING LIVES





SG10K: Insights into the genetic architecture of Singaporeans

Bellis C¹, Irwan ID¹, Lin CA¹, Koh TH¹, Wang C², Soon WW³, Wilm A⁴, Shih CC⁴, & Liu J¹ and the SG10K consortium

¹Human Genetics 2, Genome Institute of Singapore, Agency for Science, Technology and Research of Singapore (A*STAR), Singapore • ²Computational and Systems Biology, Genome Institute of Singapore, A*STAR, Singapore • ³Next Generation Sequencing Platform, Genome Institute of Singapore, A*STAR, Singapore • ⁴Scientific and Research Computing, Genome Institute of Singapore, A*STAR, Singapore

The unique ethnic diversity inherent within the Singaporean population opens it up as an opportune cohort for population genetics studies. The Singapore population consists of three major ethnic groups; Chinese, Malay, and Indian, which together represent ~80% of the genetic variation across Asian populations.

In 2015, the "SG10K project" was initiated with an overarching aim of sequencing the genomes of 10,000 Singaporeans. To date our collaborative partners include SingHealth Duke-NUS Institute of Precision Medicine, Singapore Eye Research Institute, Centre for Personalised and Precision Health, Tan Tock Seng Hospital, National University Health System and several Translational and Clinical Research Flagship Programmes (Heart failure, Parkinson disease).

Our main objectives are to (1) comprehensively characterize genetic variation in Singapore population; (2) create a WGS reference panel for accurate genotype imputation in Asian population; and (3) generate a large control dataset for WGS-based genetic association study of diseases.



Strategy


• Characterize genetic variation in Singapore


• Create a human genome reference of Singaporean population • Generate a <u>control dataset</u> for genome-wide sequencing based genetic association study of disease

- **10,000** Singaporean individuals, covering three local ethnic groups: Chinese, Malay, and Indian (representing ~80% of Asian population)
- Whole genome sequencing at 15× coverage
- IT infrastructure for data sharing with local research community and international research efforts

Precision medicine Industrial collaboration

We have adopted a shallow-pass sequencing approach, which on average will cover each base at a depth of approximately 15×. Our analytical pipeline hosted by the National Supercomputing Centre (NSCC), Singapore incorporates GATK (v3.6) and follows GATK best practices. Our initial analytical pipeline test was undertaken on n=1,059 genomes and required approximately 2-3 weeks compute time running on 20 reserved nodes at NSCC. Upon completion, this study will provide valuable genetic information to facilitate precision medicine initiatives in Singapore and will empower genetic studies of Singapore and Asiancentric diseases.





Preliminary Results

Sequencing depth

200 **d** 150 **ද** 100

N N N N

న

250

<u>p</u>

50


\$

Indian

Malay


Currently, the **SG10K** sequencing project undertaken at Genome Institute of Singapore has sequenced the first n=1,059 genomes. These genomes were used to test and optimize our pipeline for WGS analysis. We report average genome coverage of an expected ~14-15×. Furthermore, we have sequenced a further n=1,500 patient genomes from Heart Failure and Parkinson's cohorts. These genomes are being processed using the same pipeline as the first 1,000 genomes of SG10K. The analysis of the 1,500 patient samples will allow us to verify the NovogeneAIT sequencing

Whole Genome Sequence data: from GIS to remote Supercomputer in NSCC





GIS Team: JJ Liu (PI), Chaolong Wang (Co-PI), Wendy Soon (Sequencing), Andreas Wilm (Data process pipeline), Shih Chih Chuan (Data storage and database), Claire Bellis (Project Manager)



Self-reported ancestry appears consistent when compared with estimates inferred by LASER^{1,2}



SG10K is well placed heading into the next phase as we aim to sequence our remaining cohorts, totaling n~7,500 samples. We aim to ramp our efforts in the coming months to remain on track with project timelines. The initial pipeline test phase has successfully completed with preliminary metrics available for interpretation.

